Phase I Study of SRC/ABL Tyrosine Kinase Inhibitor Dasatinib [BMS-354825] in Children and Adolescents With Relapsed or Refractory Leukemia, Protocol ITCC 005
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Dasatinib (Primary)
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 05 Nov 2020 Status changed from active, no longer recruiting to completed.
- 30 May 2020 This trial has been completed in UK, according to European Clinical Trials Database.
- 14 Feb 2020 This trial has been completed in Germany, according to European Clinical Trials Database.